BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics reported revenues of $165 million, down 10.3% year on year. This print exceeded analysts’ expectations by 3.5%. Despite the top-line beat, it was still a slower quarter for the company ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

The global Immune Repertoire Sequencing Market, valued at US$344.2 million in 2024, is forecasted to grow at a robust CAGR of 9.6%, reaching ...

The global Immune Repertoire Sequencing Market, valued at US$344.2 million in 2024, is forecasted to grow at a robust CAGR of 9.6%, ...

A study by scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) introduces a more cost-effective, scalable ...